Sanofi Share News - Latest Updates, Live News & More

Latest news about Sanofi

Sanofi India Limited Publishes 70th AGM Notice Following Regulatory Requirements 10 days ago

Sanofi India Limited has published regulatory newspaper notices for its 70th Annual General Meeting scheduled for April 29, 2026. The virtual meeting will cover final dividend approval of ₹48 per share, multiple director appointments including new independent directors, and approval of significant related party transactions. Remote e-voting will be available from April 25-28, 2026.

Sanofi India Issues TDS Guidelines for Rs. 48 Final Dividend with April 22 Record Date Apr 02, 2026

Sanofi India Limited Files Business Responsibility and Sustainability Report for FY25 Apr 02, 2026

Sanofi India Receives Central Government Approval for Managing Director Appointment Apr 02, 2026

Sanofi India Publishes Newspaper Notice for 70th AGM and Final Dividend Mar 31, 2026

More news about Sanofi

28Mar 26

Sanofi India Receives Income Tax Assessment Order with ₹12.37 Crore Liability for FY 2022-23

Sanofi India Limited disclosed receiving a final income tax assessment order for FY 2022-23 with a tax liability of ₹12.37 crores including interest. The order includes adjustments on transfer pricing issues and disallowance of payments to healthcare professionals. The company plans to appeal the assessment before higher tax authorities and made this disclosure in compliance with SEBI regulations on March 28, 2026.

14Mar 26

Sanofi India Issues Notice for Transfer of Unclaimed Shares to IEPF Authority

Sanofi India Limited has issued a mandatory notice for transfer of unclaimed equity shares to the IEPF Authority. The company published newspaper advertisements on March 14, 2026, notifying shareholders who haven't claimed dividends for seven consecutive years starting from FY 2018. Affected shareholders have until June 13, 2026, to claim their dividends and shares before automatic transfer to IEPF. The company has provided contact details for its registrar MUGF Intime India Private Limited for shareholder assistance.

05Mar 26

Sanofi India Limited Releases Complete Transcript of Q4FY26 Investor Call

Sanofi India Limited has released the complete transcript of its investor/analysts call held on February 26, 2026, discussing Q4FY26 and FY25 financial results. The transcript was submitted to stock exchanges on March 5, 2026, following regulatory requirements under SEBI regulations, with management highlighting business transformation initiatives and diabetes portfolio growth.

26Feb 26

Sanofi India Q4 FY25 Results: Revenue Drops 9% YoY, Diabetes Sales Grow 6%

Sanofi India published its Q4 FY25 financial results showing mixed performance with total income declining 9% year-over-year to ₹18,571 million primarily due to 40% drop in export sales, while domestic sales remained flat with marginal 1% growth. Despite revenue challenges, net profit after tax improved 4% to ₹3,267 million, and the company proposed a 5% increase in total dividend to ₹123 per share with earnings per share rising to ₹141.85.

20Feb 26

Sanofi India Receives ₹2.37 Crore Tax Demand Order from Tamil Nadu Commercial Tax Officer

Sanofi India Limited disclosed receiving a ₹2.37 crore tax demand order from Tamil Nadu's Commercial Tax Officer for FY 2021-22, comprising ₹1.34 crore in tax, ₹89.33 lakh in interest, and ₹13.43 lakh in penalty. The dispute involves Input Tax Credit claims from FY 2020-21 that were claimed in FY 2021-22, which the tax officer rejected despite company submissions. The company plans to appeal the order before appellate authorities.

12Feb 26

Sanofi India Announces Resignation of Senior Management Personnel Mr. Suresh Babu

Sanofi India Limited announced the resignation of Mr. Suresh Babu, Sales & Customer Engagement Head – Diabetes, effective February 12, 2026. The Senior Management Personnel is leaving to pursue opportunities outside the company, with proper regulatory disclosures made under SEBI Listing Regulations.

30Dec 25

Sanofi India Limited Receives ₹1.43 Crore Tax Demand Order from CGST & Central Excise Authorities

Sanofi India Limited disclosed receiving a tax demand order of ₹1.43 crores plus equal penalty from CGST & Central Excise authorities for alleged wrong Input Tax Credit utilization during FY 2018-19 to FY 2022-23. The order was received on December 29, 2025, with additional interest charges applicable under CGST and IGST Act, 2017.

30Dec 25

Sanofi India Receives Tax Order Worth ₹14.30 Million

Sanofi India has received a tax order worth ₹14.30 million from tax authorities, as disclosed in a regulatory filing. This represents a routine regulatory matter that the pharmaceutical company will need to address through appropriate compliance procedures.

24Dec 25

Sanofi India Receives ₹24.10 Lakh GST Demand Order from Gujarat Tax Authorities

Sanofi India Limited has received a GST demand order totaling ₹24.10 lakh from the Deputy Commissioner of State Tax, Ahmedabad for FY2018-19, comprising tax of ₹12.96 lakh, interest of ₹9.85 lakh, and penalty of ₹1.30 lakh. The demand relates to excess Input Tax Credit claims in GSTR-3B compared to available ITC in GSTR-2A returns, with the company planning to appeal the decision before higher tax authorities.

18Dec 25

Sanofi India Shareholders Approve Deepak Arora as Managing Director with 94.70% Votes

Sanofi India Limited has successfully completed the shareholder approval process for Deepak Arora's appointment as Managing Director, with the postal ballot yielding 94.70% votes in favour. The remote e-voting process, conducted from November 18 to December 17, 2025, also approved his appointment as Director with 99.84% support, formally confirming the leadership transition that began in October 2025.

18Dec 25

Sanofi India Shareholders Approve Deepak Arora's Appointment as Managing Director

Sanofi India Limited successfully concluded its postal ballot process with shareholders overwhelmingly approving Deepak Arora's appointment as Director and Managing Director. The voting results showed 99.84% approval for his directorship and 94.70% for his managing director role, with 86.74% shareholder participation. Mr. Arora will serve a three-year term from October 2025 to October 2028, bringing over 30 years of pharmaceutical industry experience to lead the company.

29Oct 25

Sanofi India Reports Q3 Profit Decline, Declares ₹75 Interim Dividend

Sanofi India Limited released its Q3 financial results, showing a 9.30% decrease in revenue to ₹475.40 crore and a 7.32% drop in net profit to ₹76.00 crore. However, the company improved its EBITDA by 11.67% to ₹134.00 crore and expanded its EBITDA margin from 23.00% to 28.00%. The Board declared an interim dividend of ₹75 per equity share with a record date of November 7. Sanofi India is focusing on streamlining its portfolio and implementing cost efficiency measures.

25Sept 25

Sanofi India Announces Key Leadership Changes in Company Secretary Role

Sanofi India Limited (SIL) has announced changes in its Company Secretary and Compliance Officer position. Arjun Thakkar will resign effective September 30, 2025, to pursue a new role within the Sanofi Group. Haresh Vala, with over two decades of experience in corporate secretarial and compliance functions, will take over the position from October 1, 2025. Vala, an Associate Member of the Institute of Company Secretaries of India, will also be authorized to determine the materiality of events and make disclosures to Stock Exchanges.

02Aug 25

Sanofi India Reports Mixed Q2 2025 Results: Net Sales Decline, Operating Profit Rises

Sanofi India Limited (SIL) announced Q2 2025 results with a 9% decline in net sales but a 6% increase in operating profit year-to-date. The company's diabetes portfolio, including Soliqua® and Toujeo®, performed well in the domestic market. Strategic partnerships in Cardiovascular and Central Nervous System segments met expectations. Export sales were negatively impacted by non-recurring Consumer Healthcare product sales and planned discontinuation of the Zentiva portfolio. Management remains focused on operational efficiency and expanding access to established and innovative therapies across India.

31Jul 25

Sanofi Reports Q2 Results, Announces Leadership Changes and Strategic Partnership

Sanofi's Q2 financial results show a decline in revenue and net profit compared to Q1 and Q2 of the previous year. Revenue from operations was ₹4,063.00 million, down from ₹5,359.00 million in Q1. Net profit stood at ₹695.00 million, a decrease from ₹1,195.00 million in Q1. The company announced the retirement of Ms. Renee Amonkar and the appointment of Mr. Mahadev Gawade as the new Site Director - Goa. Sanofi also entered into a promotion and distribution agreement with Emcure Pharmaceuticals Limited for its Oral Anti-diabetic business products.

14May 25

Sanofi India: Q4 FY25 Shows Mixed Results with EBITDA Growth Despite Profit Decline

Sanofi India's Q4 FY25 results show a 25% YoY increase in EBITDA to ₹171.90 crore and an EBITDA margin rise to 32.10%. Revenue grew 5% YoY to ₹535.90 crore, with net sales up 4%. However, net profit declined 12.50% YoY to ₹119.50 crore. The launch of Soliqua® contributed to growth, highlighting operational efficiency improvements despite profit challenges.

28Feb 25

Sanofi India: Q4 Profit Surges 31%, Announces ₹117 Dividend

Sanofi India Limited (SIL) announced strong Q4 2024 results with revenue increasing 10% year-over-year to ₹515 crore and net profit jumping 31% to ₹91.3 crore. The growth was driven by a robust diabetes portfolio, successful launch of Soliqua®, and improved operational efficiency. The company's operating profit rose by 21%. The Board recommended a dividend of ₹117 per equity share for FY2024.

27Feb 25

Sanofi India Reports Mixed Q3 2024 Results with Revenue Growth and Profit Decline

Sanofi India Limited announced its Q3 2024 financial results, showing a 9.8% increase in revenue to ₹5,150 million, but a 33.8% decrease in net profit to ₹913 million. EBITDA grew by 18.5% to ₹1,180 million, with the EBITDA margin improving to 22.98%. Profit Before Tax increased by 14.8% to ₹1,140 million. An exceptional item of ₹80 million was noted, potentially impacting overall profit figures.